drugset / Trial / NCT00581789
Erlotinib and Sunitinib in NSCLC
Phase 1
Completed
11 enrolled
University of Wisconsin, Madison
Genentech, Inc. · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). * To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-02
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |